Veracyte (VCYT) SVP & General Counsel reports insider stock sale

Rhea-AI Filing Summary

Veracyte, Inc. reported an insider stock sale by its SVP and General Counsel. On 12/16/2025, the officer sold 10,639 shares of common stock at a weighted average price of $43.1277 per share and an additional 100 shares at $43.68 per share. These transactions were made under a Rule 10b5-1 trading plan adopted on August 29, 2025, which automates trades according to preset instructions. Following these sales, the reporting person beneficially owned 67,760 shares of Veracyte common stock, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McGuire Annie

(Last) (First) (Middle)

6000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/16/2025		S(1)		10,639	D	$43.1277(2)	67,860	D
Common Stock	12/16/2025		S(1)		100	D	$43.68	67,760	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025.

2. Represents weighted average sales price. Sale prices for the transactions range from $42.62 to $43.59. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Remarks:

	/s/ Jonathan Wygant, as attorney-in-fact	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Veracyte (VCYT) disclose in this Form 4?

The filing shows that Veracyte's SVP and General Counsel sold 10,639 shares of common stock at a weighted average price of $43.1277, plus an additional 100 shares at $43.68 on 12/16/2025.

How many Veracyte (VCYT) shares does the insider hold after the reported sale?

After the reported transactions, the officer beneficially owns 67,760 shares of Veracyte common stock in direct ownership.

Were the Veracyte (VCYT) insider sales made under a Rule 10b5-1 trading plan?

Yes. The filing states the transactions were made under a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025.

What were the price ranges for the Veracyte (VCYT) insider stock sales?

The filing notes a weighted average sale price of $43.1277 per share, with sale prices ranging from $42.62 to $43.59 for the reported transactions.

What is the reporting person's role at Veracyte (VCYT)?

The reporting person is identified as an officer of Veracyte, serving as SVP, General Counsel.

Is this Veracyte (VCYT) Form 4 filed for one or multiple reporting persons?

The document indicates that it is a Form filed by one reporting person, not a joint or group filing.